1. FIELD: Primary outcome
End point
Placebo (n=4900), n (%)
Fenofibrate (n=4895), n (%) HR
(95% CI) p
CHD death/
nonfatal MI
288 (6)
256 (5)
0.89
( )
0.16
CHD death
93 (2)
110 (2)
1.19
( )
0.22
Nonfatal MI
207 (4)
158 (3)
0.76
( )
0.010
The FIELD study investigators. Lancet 2005; available at:

2. FIELD: Secondary outcomes
End point
Placebo (n=4900), n (%)
Fenofibrate (n=4895), n (%) HR
(95% CI) p
Total CV events
683 (14)
612 (13)
0.89
( )
0.035
CV mortality
127 (3)
140 (3)
1.11
( )
0.41
Total mortality
323 (7)
356 (7)
( )
0.18
Stroke
175 (4)
158 (3)
0.90
( )
0.36
Coronary revascularization
364 (7)
290 (6)
0.79
( )
0.003
All revascularization
471 (10)
380 (8)
0.80
( )
0.001
The FIELD study investigators. Lancet 2005; available at: